Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
36 studies found for:    "Raynaud Disease"
Show Display Options
Rank Status Study
21 Completed PF-00489791 For The Treatment Of Raynaud's
Conditions: Raynaud's Disease;   Peripheral Vascular Disease
Intervention: Drug: PF-00489791
22 Completed Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
Conditions: Raynaud's Disease;   Scleroderma;   Autoimmune Diseases
Intervention: Drug: Topical AmphiMatrix with nitroglycerin (MQX-503)
23 Recruiting Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis
Conditions: Primary Raynaud Disease;   Systemic Sclerosis
Intervention: Biological: soluble Ve cadherin
24 Recruiting Study of Acute Peripheral Vascular Effects, Pharmacokinetics, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Condition: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions: Drug: Alprostadil;   Other: Placebo
25 Recruiting Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
Conditions: Scleroderma;   Raynaud's Syndrome
Interventions: Drug: Onabotulinumtoxin A;   Drug: sterile saline solution
26 Completed Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon
Condition: Raynaud's Phenomenon
Interventions: Drug: placebo cream;   Drug: Glyceryl Trinitrate
27 Completed Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's Syndrome
Condition: Raynaud Syndrome
Interventions: Drug: vardenafil;   Drug: Placebo
28 Terminated Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon
Condition: Raynaud's Phenomenon
Interventions: Drug: ORM-12471 30mg;   Drug: ORM-12471;   Drug: placebo
29 Active, not recruiting Raynaud's Phenomenon Secondary to Systemic Sclerosis
Condition: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions: Drug: Selexipag;   Drug: Placebo
30 Not yet recruiting Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
Condition: Secondary Raynaud's Phenomenon
Intervention: Drug: Neovasculgen
31 Completed A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Conditions: Raynaud's Phenomenon;   Digital Ulcers;   Scleroderma
Interventions: Drug: Tadalafil;   Drug: Placebo
32 Recruiting "As Required" Oral Sildenafil in Raynaud's Phenomenon
Condition: Raynaud's Phenomenon
Interventions: Drug: Sildenafil 40 mg;   Drug: Sildenafil 80 mg;   Drug: Placebo
33 Completed
Has Results
Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
Condition: Raynaud Phenomenon
Intervention: Drug: Udenafil or Amlodipine
34 Not yet recruiting Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon
Conditions: Primary Raynaud's Phenomenon (PR);   Genetic Mutations Causing PR;   Study of Patients and Their Relatives (With or Without Primary PR)
Intervention: Genetic: Demonstration of genetic mutations causing Raynaud's phenomenon
35 Completed The Effect of Physical Therapy on Raynaud`s Phenomenon Secondary to Systemic Sclerosis
Conditions: Raynaud's Phenomenon;   Systemic Sclerosis
Interventions: Other: Biofeedback;   Other: Deep oscillation
36 Completed A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
Conditions: Limited Scleroderma;   Diffuse Scleroderma
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-36) Next Page   
Indicates status has not been verified in more than two years